AB Science jumps as masitinib outperforms in Phase II trial
This article was originally published in Scrip
Executive Summary
Shares in French biotech firm AB Science shot up by as much as 72% on 2 February on Phase II data showing its investigational targeted anticancer compound masitinib was more effective and better tolerated than the current standard of care, Sutent (sunitinib), in patients with Glivec-resistant GIST.